clinical trial · NCT06968988
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Metastatic Soft-tissue SarcomaZanzalintinibIpilimumabNivolumab
brief summary
The investigators hypothesize that zanzalintinib in combination with ipilimumab and nivolumab will be well tolerated and serve as a potential therapeutic strategy in metastatic soft tissue sarcoma (mSTS) including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, and undifferentiated sarcoma histologies.
started
Jan 5, 2026
primary completion
Feb 12, 2029
completion
Jan 31, 2034
last updated
Sep 4, 2026
official title
Phase I Study With Expansion Cohort of Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol